RELMADA THERAPEUTICS ($RLMD) is expected to release its quarterly earnings data on Tuesday, March 25th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.71 per share.
You can see Quiver Quantitative's $RLMD stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RELMADA THERAPEUTICS Hedge Fund Activity
We have seen 15 institutional investors add shares of RELMADA THERAPEUTICS stock to their portfolio, and 59 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- PARSONS CAPITAL MANAGEMENT INC/RI removed 839,359 shares (-83.7%) from their portfolio in Q4 2024, for an estimated $436,466
- DEEP TRACK CAPITAL, LP removed 674,833 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $350,913
- MILLENNIUM MANAGEMENT LLC removed 561,826 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $292,149
- VESTAL POINT CAPITAL, LP removed 490,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $254,800
- OPALEYE MANAGEMENT INC. removed 480,000 shares (-100.0%) from their portfolio in Q4 2024, for an estimated $249,600
- JPMORGAN CHASE & CO removed 277,359 shares (-88.0%) from their portfolio in Q4 2024, for an estimated $144,226
- PALO ALTO INVESTORS LP removed 237,254 shares (-32.4%) from their portfolio in Q4 2024, for an estimated $123,372
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
This article was originally published on Quiver News, read the full story.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
